- Home
- VIR
as of 02-27-2026 3:52pm EST
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.0B | IPO Year: | 2019 |
| Target Price: | $29.30 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.16 | EPS Growth: | 17.49 |
| 52 Week Low/High: | $4.16 - $10.90 | Next Earning Date: | 05-25-2026 |
| Revenue: | $68,556,000 | Revenue Growth: | -7.61% |
| Revenue Growth (this year): | -87.72% | Revenue Growth (next year): | 131.58% |
| P/E Ratio: | -2.96 | Index: | N/A |
| Free Cash Flow: | -396613000.0 | FCF Growth: | N/A |
AI-Powered VIR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Vir Biotechnology Inc. (VIR)
EVP and Chief Medical Officer
Avg Cost/Share
$9.82
Shares
1,889
Total Value
$18,549.98
Owned After
154,024
SEC Form 4
EVP, General Counsel, Corp Sec
Avg Cost/Share
$9.82
Shares
13,700
Total Value
$134,534.00
Owned After
112,982
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$9.53
Shares
14,762
Total Value
$140,720.24
Owned After
1,020,704
SEC Form 4
Director
Avg Cost/Share
$10.01
Shares
42,377
Total Value
$413,366.32
Owned After
1,144,391
EVP & Chief Financial Officer
Avg Cost/Share
$9.53
Shares
1,634
Total Value
$15,576.27
Owned After
162,615
SEC Form 4
EVP and Chief Medical Officer
Avg Cost/Share
$9.53
Shares
1,616
Total Value
$15,404.68
Owned After
154,024
SEC Form 4
EVP, General Counsel, Corp Sec
Avg Cost/Share
$9.53
Shares
3,117
Total Value
$29,713.11
Owned After
112,982
SEC Form 4
SVP, Chief Accounting Officer
Avg Cost/Share
$9.53
Shares
1,430
Total Value
$13,631.62
Owned After
69,613
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$7.45
Shares
19,039
Total Value
$141,893.86
Owned After
1,020,704
SEC Form 4
EVP & Chief Financial Officer
Avg Cost/Share
$7.45
Shares
2,089
Total Value
$15,568.90
Owned After
162,615
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Eisner Mark | VIR | EVP and Chief Medical Officer | Feb 25, 2026 | Sell | $9.82 | 1,889 | $18,549.98 | 154,024 | |
| de Verneuil Vanina | VIR | EVP, General Counsel, Corp Sec | Feb 25, 2026 | Sell | $9.82 | 13,700 | $134,534.00 | 112,982 | |
| De Backer Marianne | VIR | Chief Executive Officer | Feb 24, 2026 | Sell | $9.53 | 14,762 | $140,720.24 | 1,020,704 | |
| SATO VICKI L | VIR | Director | Feb 24, 2026 | Sell | $10.01 | 42,377 | $413,366.32 | 1,144,391 | |
| O'Byrne Jason | VIR | EVP & Chief Financial Officer | Feb 24, 2026 | Sell | $9.53 | 1,634 | $15,576.27 | 162,615 | |
| Eisner Mark | VIR | EVP and Chief Medical Officer | Feb 24, 2026 | Sell | $9.53 | 1,616 | $15,404.68 | 154,024 | |
| de Verneuil Vanina | VIR | EVP, General Counsel, Corp Sec | Feb 24, 2026 | Sell | $9.53 | 3,117 | $29,713.11 | 112,982 | |
| Sabatini Brent | VIR | SVP, Chief Accounting Officer | Feb 24, 2026 | Sell | $9.53 | 1,430 | $13,631.62 | 69,613 | |
| De Backer Marianne | VIR | Chief Executive Officer | Feb 23, 2026 | Sell | $7.45 | 19,039 | $141,893.86 | 1,020,704 | |
| O'Byrne Jason | VIR | EVP & Chief Financial Officer | Feb 23, 2026 | Sell | $7.45 | 2,089 | $15,568.90 | 162,615 |
Compare VIR vs Leading Stocks
See how VIR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VIR Vir Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.